Impact of UGT1A4 Polymorphisms on the Posaconazole Serum Trough Concentrations in Patients With Acute Myeloid Leukemia Receiving Delayed-Release Tablets
The UGT1A4*3 polymorphism independently contributed to the risk of suboptimal PCZ concentrations in patients with AML taking DR tablets.
Authors
- François Parant (ORCID: https://orcid.org/0000-0002-4019-532X)
- Léa Payen (ORCID: https://orcid.org/0000-0002-1599-5886)
- Aurélien Millet
- Alexandre Deloire
- David Barthélémy (ORCID: https://orcid.org/0009-0005-6753-8096)
- Sophie Ducastelle-Leprêtre
- Marie‐Claude Gagnieu
- Laurie Di-Pilla
- Anaëlle Joassard
Institutions
- Université Claude Bernard Lyon 1 (FR)
Publication Details
- Journal
- Therapeutic Drug Monitoring
- Published
- 2025-03-04
- DOI
- https://doi.org/10.1097/ftd.0000000000001319
- Citations
- 1
- Primary Topic
- Neutropenia and Cancer Infections
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- MSD France